publication date: Jan. 8, 2021
Issue 1 - Jan. 8, 2021
  • Guest Editorial

    Paskett: A three-time cancer survivor should not get COVID-19, but I did

    Cancer patients and survivors should not get COVID-19. A three-time cancer survivor should definitely not get COVID. But I did. And it was not good. Here is my story and the lessons I learned that might be of value to others.

  • Letter from the Editor & Publisher

    Presenting the Cancer History Project

    Historical documents have a way of vanishing. Manuscripts, letters, and photographs end up in city dumps. Memories become less granular, insight is lost. The documents that do get preserved often require a trip to the archives.

  • Cancer groups urge CDC to prioritize cancer patients for COVID-19 vaccination

    The American Cancer Society and the Association of Clinical Oncology are calling on the Centers for Disease Control and Prevention to give cancer patients a higher priority amid the rollout of vaccines against SARS-CoV-2.

  • Top 25 stories of 2020

    The year 2020 was, by any reckoning, one that most of us would prefer to relegate to history books—fun to read about, and hopefully not condemned to repeat.

  • Mace Rothenberg steps down as Pfizer CMO, replaced by Stanford’s Aida Habtezion

    Mace Rothenberg has stepped down as chief medical officer at Pfizer. His successor is Aida Habtezion, a Stanford researcher whose work is focused on leukocyte recruitment and immune responses in diseases affecting the digestive organs. 

  • In Brief

    • Welela Tereffe named chief medical executive at MD Anderson
    • Adam Marcus named interim executive director of Winship Cancer Institute of Emory University
    • Angela L. Talton named first chief diversity, equity and inclusion officer at City of Hope
    • Kashyap Patel elected president of COA
    • Steven Lemery named acting associate director of Tissue Agnostic Drug Development at FDA’s OCE
    • Roy Herbst, Worta McCaskill-Stevens, and Lawrence Shulman receives 2020 ACCC awards
    • Kristin Ferguson named senior director of ACCC
    • Melissa Johnson named program director of lung cancer research at Sarah Cannon
    • John Ryan named senior vice president and general counsel at Dana-Farber
    • Rutgers Cancer Institute of New Jersey receives $25 million for Cancer Immunology and Metabolism Center of Excellence
    • SU2C receives $10 million Exact Sciences grant for colorectal cancer screening and prevention initiative
    • Northwell opens $6.2 million cancer center in Riverhead NY
    • Mark Foundation awards five grants to accelerate a new class of cancer drugs based on induced proximity
    • National Association for Proton Therapy establishes Physician Advisory Committee
    • U.S. government passes law honoring legacy of Henrietta Lacks by increasing access to clinical trials
    • Massachusetts health care law expected to improve access to clinical trials
  • TCCL Logo

  • Clinical Roundup

    • Study: Striking differences seen in COVID-19 responses in cancer patients
    • American College of Surgeons study reports drop in lung cancer screening, rise in malignancy rates during spring COVID-19 surge
    • Largest, most diverse ever study of prostate cancer genetics brings disparities into focus
    • New NCCN resource for survivors helps guide life after cancer diagnosis and treatment
    • Triple chemotherapy combination improves metastatic colorectal cancer outcomes
    • Miami Cancer Institute launches new and expanded clinical trials for COVID-19 treatments
    • Phase III Keytruda + Lenvima study shows improved OS, PFS in advanced endometrial cancer
    • Cabometyx significantly improved PFS in phase III trial of previously treated radioiodine-refractory differentiated thyroid cancer
    • Ohio State launches statewide study focused on breast cancer in Black women
    • Roswell Park researchers: Aggressive breast cancers in Black patients are related to immune factors
    • UCLA study: More women embracing ‘going flat’ after mastectomy
    • New combination therapy could help fight difficult-to-treat cancers with common mutations
  • Drugs & Targets

    • Tagrisso receives FDA approval as adjuvant therapy for NSCLC with EGFR mutations
    • Iclusig receives FDA sNDA approval for adult patients with resistant or intolerant chronic-phase CML
    • Xpovio receives FDA approval for refractory or relapsed multiple myeloma
    • Orgovyx receives FDA approval for advanced prostate cancer
    • Margenza receives FDA approval for metastatic HER2-positive breast cancer
    • CPI-613 receives FDA Fast Track Designation for treatment of AML
    • EU CHMP issues positive opinion for Keytruda as first-line treatment in adult patients in colorectal cancer indication
    • Bayer and Veracyte collaborate on precision oncology in thyroid cancer
    • Servier to acquire Agios Pharmaceuticals’ oncology business
    • Kite and Oxford BioTherapeutics establish cell therapy research collaboration in blood cancers and solid tumors
  • NCI Trials

    NCI Trials for Jan. 2021

    The National Cancer Institute approved the following clinical research studies last month. 

Copyright (c) 2020 The Cancer Letter Inc.